Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

Company Overview - Pharvaris is a late-stage biopharmaceutical company focused on developing novel, oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [2] - The company aims to provide injectable-like efficacy and placebo-like tolerability with the convenience of an oral therapy for the prevention and treatment of HAE attacks [2] Clinical Development - Pharvaris is currently evaluating the efficacy and safety of its drug, deucrictibant, in pivotal Phase 3 studies: one for the prevention of HAE attacks (CHAPTER-3) and another for the on-demand treatment of HAE attacks (RAPIDe-3) [2] Upcoming Events - Pharvaris management will participate in the Leerink Partners Global Healthcare Conference 2025, scheduled for March 10-12, 2025, in Miami, FL [1] - CEO Berndt Modig will be featured in a fireside chat on March 10 at 9:20 a.m. ET, with a live audio webcast available on the company's website [1]